Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib + surufatinib neoadjuvant study in advanced ovarian cancer
ChiCTR2300069295Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib and surufatinib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: R0 resection rate. Started Mar 2023; status: recruiting.
02
Drugs
pamiparibsurufatinib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2300069295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069295.